AstraZeneca Reports First Patient Dosing in P-III PACIFIC-9 Study for NSCLC
Shots:
- The first patient has been dosed in P-III PACIFIC-9 study evaluating durvalumab (PD-L1) + monalizumab (NKG2A) or oleclumab (anti-CD73) in patients with unresectable, stage III NSCLC who have not progressed following definitive Pt.-based concurrent CRT. The study is looking to recruit patients across 200+ centres
- The focus of the study is to determine if the addition of monalizumab or oleclumab to SOC durvalumab improves outcomes for patients in this setting
- The first dosing has triggered a $50M milestone payment from AstraZeneca to Innate. Innate’s monalizumab is an immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor-infiltrating cytotoxic CD8+ T cells and NK cells
Ref: Innate | Image: Innate
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.